Results 21 to 30 of about 30,729 (226)

Naltrexone plus Bupropion Combination Medication Maintenance Treatment for Binge-Eating Disorder Following Successful Acute Treatments: Randomized Double-Blind Placebo-Controlled Trial

open access: yesPsychological Medicine, 2023
Background Certain treatments have demonstrated acute efficacy for binge-eating disorder (BED) but there is a dearth of controlled research examining pharmacotherapies as maintenance treatments for responders to initial interventions.
C. Grilo   +2 more
semanticscholar   +1 more source

Delayed onset urticaria in depressive patients with bupropion prescription: a nationwide population-based study. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: Bupropion, which is widely used in patients with depressive disorder, may cause allergic reactions. However, the real prevalence of these side effects may be overlooked and underreported due to the delayed onset phenomenon.
Li-Yu Hu   +16 more
doaj   +1 more source

Acute intoxication following massive bupropion sniffing: A case report

open access: yesEmergency Care Journal, 2021
Bupropion intranasal misuse potential should be considered in the suspect of sympathomimetic syndrome for illicit drug or medication intoxication. A 31-year-old man was admitted for intranasal misuse of 30 crushed tablets of bupropion with adrenergic ...
Simone Sartori   +7 more
doaj   +1 more source

Dextromethorphan/Bupropion: First Approval

open access: yesCNS Drugs, 2022
An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the antidepressant bupropion hydrochloride (an aminoketone and CYP2D6 inhibitor that ...
S. Keam
semanticscholar   +1 more source

Part Two: Evaluation of N-methylbupropion as a Potential Bupropion Prodrug

open access: yesPharmaceuticals, 2014
N-methylbupropion was selected as a potential prodrug from our in vitro screening of analogues of bupropion described in the preceding paper. This study describes in vivo pharmacokinetics of N-methylbupropion in the guinea-pig animal model, which is ...
Paul Matthew O'Byrne   +3 more
doaj   +1 more source

Visual hallucinations associated with bupropion use: a case report

open access: yesPsychiatry and Clinical Psychopharmacology, 2021
Bupropion is an antidepresant that acts as a norepinephrine and dopamine reuptake inhibitor and has a favorable side-effect profile. The most common side-effects of this drug include insomnia, constipation, headache and dry mouth.
Sevda Korkmaz   +3 more
doaj   +1 more source

Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials

open access: yesIndian Journal of Psychiatry, 2023
According to the Global Burden of Disease (GBD) Study conducted in 2019, smoking tobacco leads to over 8 million deaths each year. Hence, it is crucial to identify optimal smoking cessation therapy. To compare the efficacy of varenicline versus bupropion
Ashish R. Patel   +2 more
doaj   +1 more source

A novel dosage form for buccal administration of bupropion

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2015
Bupropion is an antidepressant used in the treatment of smoking. The purpose of this study was to prepare controlled-release hydrogel films for buccal administration of bupropion and investigate its physicochemical and cytotoxic properties.
Nilsa Maria Galvão Almeida   +5 more
doaj   +1 more source

Naltrexone-bupropion (Mysimba®) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports.

open access: yesBritish Journal of Clinical Pharmacology, 2020
AIMS To compare the benefits and harms of naltrexone-bupropion using evidence from clinical study reports (CSRs). METHODS We searched FDA and EMA websites, PubMed, and Clinicaltrials.gov (May 2016) to identify pivotal trials; we then sent a freedom of ...
I. Onakpoya   +4 more
semanticscholar   +1 more source

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2022
Sarah Dahlberg,1 Ellen T Chang,1 Sheila R Weiss,1 Pamela Dopart,1 Errol Gould,2 Mary E Ritchey3 1Exponent, Inc, Menlo Park, CA, 94025, USA; 2Currax Pharmaceuticals LLC., Brentwood, TN, 37027, USA; 3Med Tech Epi, LLC., Philadelphia, PA, 19147 ...
Dahlberg S   +5 more
doaj  

Home - About - Disclaimer - Privacy